Endometrial response following percutaneous estrogen replacement therapy. A morphometric investigation. 1983

S Cajander, and J Holst, and K Carlström, and M G Damber, and B von Schoultz

The endometrial response in 10 postmenopausal women receiving estrogen replacement therapy was evaluated morphologically and quantified by morphometric analysis. During 6 months of cyclic treatment with percutaneous estradiol-17 beta, 3 mg daily, the mean relative endometrial gland volume increased from 10% to 40%. In each individual woman this morphometric parameter was significantly correlated to the serum concentration of estradiol-17 beta. The decline in FSH level during treatment showed no significant correlation to the endometrial response or the estrogen level. In some endometrial samples from women during treatment, glands with incomplete epithelial lining and rows of glandular epithelial cells were observed. It is suggested that these phenomena represent early forms of glandular development.

UI MeSH Term Description Entries
D008593 Menopause The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age. Change of Life, Female
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004717 Endometrium The mucous membrane lining of the uterine cavity that is hormonally responsive during the MENSTRUAL CYCLE and PREGNANCY. The endometrium undergoes cyclic changes that characterize MENSTRUATION. After successful FERTILIZATION, it serves to sustain the developing embryo. Endometria
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D005260 Female Females
D005640 Follicle Stimulating Hormone A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Follicle-stimulating hormone stimulates GAMETOGENESIS and the supporting cells such as the ovarian GRANULOSA CELLS, the testicular SERTOLI CELLS, and LEYDIG CELLS. FSH consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity. FSH (Follicle Stimulating Hormone),Follicle-Stimulating Hormone,Follitropin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001284 Atrophy Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes. Atrophies
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

S Cajander, and J Holst, and K Carlström, and M G Damber, and B von Schoultz
January 1983, Acta obstetricia et gynecologica Scandinavica. Supplement,
S Cajander, and J Holst, and K Carlström, and M G Damber, and B von Schoultz
May 1996, Maturitas,
S Cajander, and J Holst, and K Carlström, and M G Damber, and B von Schoultz
March 1996, Gynecologic oncology,
S Cajander, and J Holst, and K Carlström, and M G Damber, and B von Schoultz
February 1990, Gynecologic oncology,
S Cajander, and J Holst, and K Carlström, and M G Damber, and B von Schoultz
January 1977, Frontiers of hormone research,
S Cajander, and J Holst, and K Carlström, and M G Damber, and B von Schoultz
June 1996, JAMA,
S Cajander, and J Holst, and K Carlström, and M G Damber, and B von Schoultz
June 1996, JAMA,
S Cajander, and J Holst, and K Carlström, and M G Damber, and B von Schoultz
August 1997, Journal of the National Cancer Institute,
S Cajander, and J Holst, and K Carlström, and M G Damber, and B von Schoultz
January 1998, Journal of the National Cancer Institute,
S Cajander, and J Holst, and K Carlström, and M G Damber, and B von Schoultz
December 1976, Clinical obstetrics and gynecology,
Copied contents to your clipboard!